The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > COLUMN
COLUMN
-
How to Be a Country Manager
November 29, 2024
-
Elevating Leadership: Insights from Japan’s Healthcare Sector
October 23, 2024
-
6 Tips for Motivating and Engaging Current Employees
September 30, 2024
-
Why LinkedIn Isn’t Effective in Japan
August 27, 2024
-
The Dynamics of Field Medical Visits: Importance of Balancing Quality and Frequency in Medical Interactions
August 2, 2024
-
3 Common Mistakes Made when Hiring a Leader
July 25, 2024
-
3 Tips for Establishing Local Connections in Japan
June 28, 2024
-
How to Plan for Future Talent Needs
May 31, 2024
-
Boosting Employee Retention in a Competitive Market
April 18, 2024
-
How to Paint an Irresistible Picture of Success
March 22, 2024
-
Positioning Your Company as an Employer of Choice
February 22, 2024
-
Navigating the Evolving Landscape of Medical Affairs: Integrating Insights and Identity for Future Success
February 7, 2024
-
How NOT to Write a Job Description
January 26, 2024
-
Goal-Setting for 2024: Crushing It
December 20, 2023
-
The Power of Referrals and Who to Ask
November 24, 2023
-
How Can Innovative Field Force Roles and Ways of Working Create More Impactful Engagement?
November 2, 2023
-
3 Strategies for Attracting Talent Who Aren’t Looking for a Job
October 18, 2023
-
How Can You Improve Field Force Productivity in the Age of Digital? Omnichannel Excellence and the Importance of a Strong “Middle Layer”
October 6, 2023
-
How to Get 4 Qualified Candidates within 4 Weeks
September 25, 2023
-
How Far Has Your Organization Come? Key Lessons Learned from Ongoing Commercial Transformations in Japan
September 11, 2023
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…